Neurology News

AUSTIN, Texas — Treatment with candesartan led to significant reduction in mean monthly headache days and headache intensity in adolescents with high baseline migraine frequency, according to a poster presented here.

In this edition, Leqembi shows benefits in early Alzheimer’s, sex before bed has more positive impact on sleep, clearer guidelines needed on melatonin use in children and more.

ORLANDO — An initiative that focused on surgical patients’ paths from pre-op meetings to hospital discharge reduced neurosurgical infections by more than 80% over 2 years at a Pittsburgh hospital, researchers reported.

AUSTIN, Texas — Treatment with 10 mg zavegepant nasal spray resulted in better quality of life as early as 12 weeks and through 1 year in adult patients with migraine, according to research presented here.

The FDA has removed the clinical hold on the investigational new drug application for the phase 2/3 ReMEDy2 trial of DM199 for acute ischemic stroke, DiaMedica Therapeutics announced in a press release.

The FDA has approved Rystiggo, a subcutaneous infusion therapy to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.

In patients with minor nondisabling acute ischemic stroke, treatment with dual antiplatelet therapy was noninferior to treatment with IV alteplase, according to the results of the ARAMIS trial.

Topline data from a phase 2a, multiple ascending dose study identified a maximum tolerated dose for development of AL001, an investigational lithium-delivery system, according to a press release from manufacturer Alzamend Neuro.

Last week, Healio provided live coverage of the American Headache Society Annual Meeting in Austin, Texas, where health care professionals gathered for the latest updates on headache disorders.

INDIANAPOLIS — Greater daytime sleepiness scores were associated with worse sleep-dependent memory consolidation in women, Kimberly Espejo said in a presentation at SLEEP 2023.